PriceTargets.com logo

Chimerix - CMRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 797.87%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.89 As of 04/25/2024 01:00 AM ET
▼ -0.02 (-2.20%)

This chart shows the closing price for CMRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chimerix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMRX

Analyst Price Target is $8.00
▲ +797.87% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Chimerix in the last 3 months. The average price target is $8.00, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 797.87% upside from the last price of $0.89.

This chart shows the closing price for CMRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Chimerix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
2/12/2024WedbushReiterated RatingOutperform$6.00Low
11/2/2023WedbushReiterated RatingOutperform$6.00Low
8/16/2023WedbushReiterated RatingOutperform ➝ Outperform$6.00Low
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
5/22/2023Robert W. BairdInitiated CoverageOutperform$7.00Low
3/3/2023HC WainwrightReiterated RatingBuy$11.00Low
9/7/2022Capital One FinancialInitiated CoverageOverweight$7.00Low
5/17/2022Maxim GroupLower TargetNA$6.00High
5/17/2022CowenLower TargetNA$10.00High
5/16/2022WedbushReiterated RatingOutperformHigh
5/16/2022HC WainwrightLower TargetBuy$24.00 ➝ $11.00N/A
12/22/2021HC WainwrightReiterated RatingBuy$21.00 ➝ $24.00High
11/22/2021WedbushLower TargetOutperform$15.00 ➝ $14.00Medium
11/22/2021HC WainwrightBoost TargetPositive ➝ Buy$19.00 ➝ $21.00Low
11/5/2021Maxim GroupReiterated RatingBuy$20.00Low
8/6/2021Maxim GroupReiterated RatingBuy$20.00Medium
6/7/2021HC WainwrightBoost TargetBuy$18.00 ➝ $19.00High
5/6/2021HC WainwrightBoost TargetBuy$16.00 ➝ $18.00High
4/29/2021Maxim GroupInitiated CoverageBuy$20.00High
4/12/2021JonestradingReiterated RatingBuy$14.00High
3/31/2021Jefferies Financial GroupInitiated CoverageBuy$21.00High
3/31/2021WedbushInitiated CoverageOutperform$21.00High
1/11/2021HC WainwrightBoost TargetBuy$7.00 ➝ $16.00High
1/8/2021JonestradingReiterated RatingBuy$10.00High
8/11/2020HC WainwrightReiterated RatingBuy$7.00High
2/26/2020HC WainwrightReiterated RatingBuy$7.00High
8/1/2019HC WainwrightBoost TargetBuy$5.00 ➝ $7.00Medium
5/9/2019CowenReiterated RatingHold$3.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $0.89
Low: $0.88
High: $0.94

50 Day Range

MA: $1.07
Low: $0.88
High: $1.26

52 Week Range

Now: $0.89
Low: $0.88
High: $1.57

Volume

242,657 shs

Average Volume

393,188 shs

Market Capitalization

$79.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Chimerix?

The following Wall Street research analysts have issued research reports on Chimerix in the last year: HC Wainwright, Robert W. Baird, StockNews.com, and Wedbush.
View the latest analyst ratings for CMRX.

What is the current price target for Chimerix?

3 Wall Street analysts have set twelve-month price targets for Chimerix in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 797.9%. HC Wainwright has the highest price target set, predicting CMRX will reach $11.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $6.00 for Chimerix in the next year.
View the latest price targets for CMRX.

What is the current consensus analyst rating for Chimerix?

Chimerix currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMRX will outperform the market and that investors should add to their positions of Chimerix.
View the latest ratings for CMRX.

What other companies compete with Chimerix?

Other companies that are similar to Chimerix include LifeVantage, Q32 Bio, Leap Therapeutics, Affimed and Eton Pharmaceuticals. Learn More about companies similar to Chimerix.

How do I contact Chimerix's investor relations team?

Chimerix's physical mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company's listed phone number is (919) 806-1074 and its investor relations email address is [email protected]. The official website for Chimerix is www.chimerix.com. Learn More about contacing Chimerix investor relations.